MX375783B - Composiciones farmacéuticas que comprenden un compuesto de formoterol, un corticosteroide y un componente propelente. - Google Patents

Composiciones farmacéuticas que comprenden un compuesto de formoterol, un corticosteroide y un componente propelente.

Info

Publication number
MX375783B
MX375783B MX2018006800A MX2018006800A MX375783B MX 375783 B MX375783 B MX 375783B MX 2018006800 A MX2018006800 A MX 2018006800A MX 2018006800 A MX2018006800 A MX 2018006800A MX 375783 B MX375783 B MX 375783B
Authority
MX
Mexico
Prior art keywords
formoterol
component
corticosteroid
propellent
pharmaceutical compositions
Prior art date
Application number
MX2018006800A
Other languages
English (en)
Spanish (es)
Other versions
MX2018006800A (es
Inventor
Stuart Corr
Timothy James Noakes
Original Assignee
Mexichem Fluor Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57750288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX375783(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1521456.2A external-priority patent/GB201521456D0/en
Priority claimed from GB1615916.2A external-priority patent/GB2554092A/en
Application filed by Mexichem Fluor Sa De Cv filed Critical Mexichem Fluor Sa De Cv
Publication of MX2018006800A publication Critical patent/MX2018006800A/es
Publication of MX375783B publication Critical patent/MX375783B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2018006800A 2015-12-04 2016-12-02 Composiciones farmacéuticas que comprenden un compuesto de formoterol, un corticosteroide y un componente propelente. MX375783B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1521456.2A GB201521456D0 (en) 2015-12-04 2015-12-04 Pharmaceutical composition
GB1615916.2A GB2554092A (en) 2016-09-19 2016-09-19 Pharmaceutical composition
PCT/GB2016/053812 WO2017093758A1 (en) 2015-12-04 2016-12-02 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
MX2018006800A MX2018006800A (es) 2018-11-09
MX375783B true MX375783B (es) 2025-03-07

Family

ID=57750288

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006800A MX375783B (es) 2015-12-04 2016-12-02 Composiciones farmacéuticas que comprenden un compuesto de formoterol, un corticosteroide y un componente propelente.

Country Status (10)

Country Link
US (3) US11559505B2 (enExample)
EP (4) EP3383366B2 (enExample)
JP (3) JP6899824B2 (enExample)
CN (2) CN108289843B (enExample)
AU (3) AU2016364650B2 (enExample)
BR (2) BR122020022602B1 (enExample)
CA (1) CA3007050C (enExample)
ES (3) ES2869176T3 (enExample)
MX (1) MX375783B (enExample)
WO (1) WO2017093758A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6899824B2 (ja) 2015-12-04 2021-07-07 メキシケム フロー エセ・ア・デ・セ・ヴェ 薬学的組成物
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
EP3922240B1 (en) * 2016-09-19 2023-06-21 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising tiotropium bromide
WO2018051128A1 (en) 2016-09-19 2018-03-22 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
CN109715148A (zh) * 2016-09-19 2019-05-03 墨西哥氟石股份公司 药物组合物
CN109789126B (zh) 2016-09-19 2022-08-05 墨西哥氟石股份公司 药物组合物
PH12019500577B1 (en) * 2016-09-19 2023-09-08 Mexichem Fluor Sa De Cv Pharmaceutical composition
CN109771398B (zh) * 2019-02-25 2019-09-20 广州南鑫药业有限公司 一种帕拉米韦溶液型吸入剂及其制备方法
GB2584686A (en) * 2019-06-11 2020-12-16 Mexichem Fluor Sa De Cv Methods
CN110840864B (zh) * 2019-12-20 2022-02-22 广州健康元呼吸药物工程技术有限公司 一种β2受体激动剂吸入气雾剂及包含该吸入气雾剂的产品
JP2023511615A (ja) * 2020-01-28 2023-03-20 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 緩衝化医薬製剤を含む加圧定量吸入器
GB202001537D0 (en) * 2020-02-05 2020-03-18 Consort Medical Plc Pressurised dispensing container
WO2021165348A1 (en) * 2020-02-20 2021-08-26 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
CN116338014A (zh) * 2021-12-23 2023-06-27 上海医药工业研究院有限公司 一种吸入用药物组合物的组分分离检测方法
FR3137830A1 (fr) * 2022-07-13 2024-01-19 Aptar France Sas Composition pharmaceutique comprenant du salbutamol

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
IE67185B1 (en) 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
MX9203481A (es) 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US6123924A (en) 1991-09-25 2000-09-26 Fisons Plc Pressurized aerosol inhalation compositions
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
SG48301A1 (en) * 1991-12-18 1998-04-17 Astra Ab New combination
MY131733A (en) 1994-12-22 2007-08-30 Astra Ab Aerosol drug formulations
JPH11503352A (ja) 1995-04-14 1999-03-26 グラクソ、ウェルカム、インコーポレーテッド プロピオン酸フルチカゾン用計量投与用吸入器
EP1014943B1 (de) 1997-02-05 2002-06-19 Jago Research Ag Medizinische aerosolformulierungen
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
JP2003525842A (ja) 1997-09-29 2003-09-02 インヘール セラピューティック システムズ, インコーポレイテッド 計量吸入器における使用のための安定化調製物
US6103266A (en) 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
DE59904648D1 (de) 1998-08-04 2003-04-24 Jago Res Ag Muttenz Medizinische aerosolformulierungen
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
GB2392915B (en) 1999-09-11 2004-04-28 Glaxo Group Ltd Pharmaceutical formulation of fluticasone propionate
US6432415B1 (en) 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
UA73986C2 (uk) 2000-05-22 2005-10-17 К'Єзі Фармачеутічі С.П.А. АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ
CN1144582C (zh) 2000-11-28 2004-04-07 中国药科大学 治疗呼吸系统疾病的无氟里昂药用气雾剂
TWI324934B (en) 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
SE0200312D0 (sv) * 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US8039746B2 (en) 2002-08-08 2011-10-18 Fujikura Ltd. Electric connector and cable
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
WO2006004646A1 (en) 2004-06-28 2006-01-12 Nektar Therapeutics Aerosol formulation comprising nicotine salt
ES2259915B1 (es) * 2005-03-15 2007-12-16 Laboratorio Aldo-Union, S.A. Nueva formulacion estable de aerosoles en suspension y procedimiento de obtencion.
WO2007020204A2 (en) 2005-08-12 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate
DE102006017320A1 (de) 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
EP2117504A1 (en) 2007-02-09 2009-11-18 Schering Corporation Stable pharmaceutical drug aerosols
WO2009088553A1 (en) * 2007-10-22 2009-07-16 Board Of Regents, The University Of Texas System Dry powder drug delivery formulations, methods of use, and devices therefore
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
GB0915106D0 (en) 2009-08-28 2009-10-07 Glaxo Group Ltd Process
PL2727582T3 (pl) * 2009-10-02 2016-06-30 Chiesi Farm Spa Farmaceutyczne formulacje aerozolowe formoterolu i dipropionianu beklometazonu
PE20121467A1 (es) 2009-12-23 2012-11-07 Chiesi Farma Spa Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica
CN105412122A (zh) * 2010-07-16 2016-03-23 希普拉有限公司 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物
MX2013009525A (es) * 2011-02-17 2013-10-01 Cipla Ltd Combinacion de glicopirrolato y un beta2-agonista.
GB201108039D0 (en) 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) * 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117621D0 (en) * 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
CN102362860A (zh) 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
WO2014016548A2 (en) 2012-07-27 2014-01-30 Cipla Limited Pharmaceutical composition
KR20150096371A (ko) * 2012-10-23 2015-08-24 시플라 리미티드 티오트로피움 및 히드로플루오로알칸을 포함하는 약학적 조성물
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
RS57687B1 (sr) 2013-12-30 2018-11-30 Chiesi Farm Spa Pod pritiskom stabilan aerosolni rastvor kompozicije glikopironijum bromida i kombinacije formoterola
JP6899824B2 (ja) 2015-12-04 2021-07-07 メキシケム フロー エセ・ア・デ・セ・ヴェ 薬学的組成物
CN109715148A (zh) 2016-09-19 2019-05-03 墨西哥氟石股份公司 药物组合物

Also Published As

Publication number Publication date
EP3383366B2 (en) 2024-06-05
JP6899824B2 (ja) 2021-07-07
AU2019202874C1 (en) 2020-08-06
EP3383366B1 (en) 2020-03-25
JP2019500340A (ja) 2019-01-10
AU2019202875A1 (en) 2019-05-16
JP2020073516A (ja) 2020-05-14
BR112018011266B1 (pt) 2023-11-21
AU2019202875B2 (en) 2020-03-12
US11559506B2 (en) 2023-01-24
JP6931383B2 (ja) 2021-09-01
EP3701940B1 (en) 2025-11-12
US20190247339A1 (en) 2019-08-15
EP3556348A1 (en) 2019-10-23
CA3007050C (en) 2020-12-08
US11559505B2 (en) 2023-01-24
AU2016364650B2 (en) 2019-04-04
JP6899889B2 (ja) 2021-07-07
AU2019202874B2 (en) 2020-03-12
EP3556347A1 (en) 2019-10-23
EP3383366A1 (en) 2018-10-10
ES2796177T3 (es) 2020-11-26
AU2016364650A1 (en) 2018-06-21
CN112472689A (zh) 2021-03-12
US20200009089A1 (en) 2020-01-09
BR112018011266A2 (pt) 2018-11-21
CA3007050A1 (en) 2017-06-08
MX2018006800A (es) 2018-11-09
JP2020073515A (ja) 2020-05-14
ES2796177T5 (es) 2024-10-29
EP3556347B1 (en) 2021-03-24
CN108289843B (zh) 2021-08-17
ES2866175T3 (es) 2021-10-19
BR122020022602B1 (pt) 2024-03-05
AU2019202874A1 (en) 2019-05-16
US11559507B2 (en) 2023-01-24
CN108289843A (zh) 2018-07-17
EP3556348B1 (en) 2021-02-03
CN112472689B (zh) 2023-01-17
US20200069619A1 (en) 2020-03-05
ES2869176T3 (es) 2021-10-25
EP3701940A1 (en) 2020-09-02
WO2017093758A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
MX375783B (es) Composiciones farmacéuticas que comprenden un compuesto de formoterol, un corticosteroide y un componente propelente.
MX375784B (es) Composiciones farmacéuticas que comprenden al menos un compuesto de mometasona y un componente propelente.
PH12016502255A1 (en) Combination
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
ZA201902051B (en) Pharmaceutical composition
ZA201902053B (en) Pharmaceutical composition
MX381707B (es) Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
MX376028B (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
MX389802B (es) Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos.
MX2021010022A (es) Composicion farmaceutica.
ZA201902052B (en) Pharmaceutical composition
UY37800A (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
ZA201902049B (en) Pharmaceutical composition
MX2017009482A (es) Formulación farmacéutica.
BR112022004677A2 (pt) Composição oftálmica para o tratamento de uveíte
PH12017502426A1 (en) Solid pharmaceutical compositions for treating hcv
PH12018500132A1 (en) Solid pharmaceutical compositions for treating hcv
MX2019000977A (es) Composiciones farmacéuticas a base de curcumina y procedimientos para su fabricación.
MX2018010652A (es) Composiciones farmaceuticas.
MX2019001425A (es) Composiciones y el uso de las mismas para el tratamiento o la prevención de la rosácea.
HK1230967A1 (en) Combination
BR112017017774A2 (pt) composto, composição farmacêutica e método para fabricar um medicamento
BR112017006998A2 (pt) compostos de aminopurina substituídos, composições dos mesmos e métodos de tratamento com os mesmos

Legal Events

Date Code Title Description
FG Grant or registration